Jaime Goodman, MD
Endocrinology, Diabetes & Metabolism · Mount Vernon, OHNPI 1790949006
Payments from drug & device makers
Across 1,113 payments — averaging $58.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$36K
- Lilly USA, LLC$8K
- Boehringer Ingelheim$7K
- Novo Nordisk$5K
- Amgen$1K
- AstraZeneca$1K
- plus $8K from 35 others
What the payments were for
- Consulting fees$1,6202%
- Speaking & faculty fees$43,39767%
- Travel & lodging$2,2153%
- Food & beverage$17,34827%
- Education$2270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$20,334
- TOUJEO$11,905
- JARDIANCE$11,783
- RYBELSUS$1,620
- Ozempic$236
- Korlym$227
- AFREZZA$145
- FREESTYLE LIBRE 3$144
- Minimed 530G$137
- Prolia$122
- EVENITY$122
- Tresiba$111
- MYALEPT$110
- Wegovy$101
How this compares
$64,806 in reported general payments places this provider in the 85th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 302 | $485,145 |
| JardianceEmpagliflozin | 205 | $255,357 |
| FarxigaDapagliflozin Propanediol | 195 | $239,371 |
| TrulicityDulaglutide | 152 | $215,800 |
| JanuviaSitagliptin Phosphate | 154 | $138,045 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 81 | $114,884 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $94,816 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 58 | $93,184 |
| VascepaIcosapent Ethyl | 144 | $84,760 |
| MounjaroTirzepatide | 55 | $75,266 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 53 | $71,926 |
| RybelsusSemaglutide | 24 | $54,798 |
| Tresiba Flextouch U-100Insulin Degludec | 71 | $53,716 |
| Novolog FlexpenInsulin Aspart | 153 | $53,631 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $50,555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Fiasp, Novolog | $4,616 | $682,788446 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $6,788 | $296,430261 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $7,918 | $291,066207 claims |
| AstraZenecaFarxiga | $1,001 | $239,371195 claims |
| MerckJanuvia | $473 | $138,045154 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $35,659 | $93,18458 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $345 | $38,93230 claims |
| Radius Health, Inc.Tymlos | $178 | $28,50911 claims |
| AbbVieSynthroid | $491 | $10,038163 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $9,715907 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Mount Vernon
- Toby BriskinBedford$9.8M
- Charles SmithCanton$5.3M
- Kevin PantaloneCleveland$4M
- Elena ChristofidesColumbus$3.5M
- Arvind KrishnaCanton$3.1M
- Bartolome BurgueraCleveland$3.1M
- Steven IngColumbus$1.9M
- Kathleen DunganColumbus$1.4M
- Kyaw SoeColumbus$1.3M
- John PaesWesterville$671K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.